Healthcare / Medical Care FacilitiesHKSE
$2.68
-0.03 (-1.12%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 24% · confianza 25%
FCF escenarios
weak_data · normalized FCF $708.4M · quality 82.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
48/100
C
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$3.4B
P/E
5.9x
↓EV/EBITDA
2.4x
↓ROE
7.6%
↑Gross Margin
15.7%
↓Debt/Equity
0.13
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+5.1%
FCF CAGR
+28.6%
FCF margin
9.2%
FCF / Net income
1.70x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $9.18B · net income $495.9M · FCF $844.4M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $9.18B | $9.18B | $9.85B | $10.11B | $7.90B |
| Net Income | $495.9M | $495.9M | $565.9M | $257.7M | $265.9M |
| EBITDA | $1.36B | $1.36B | $1.52B | $1.22B | $965.2M |
| EPS | — | — | 0.45 | 0.20 | 0.21 |
| Gross Margin | 15.7% | 15.7% | 18.4% | 18.9% | 16.5% |
| Operating Margin | 5.0% | 5.0% | 7.9% | 9.5% | 6.4% |
| Net Margin | 5.4% | 5.4% | 5.7% | 2.5% | 3.4% |
| Balance Sheet | |||||
| Debt/Equity | 0.13 | 0.13 | 0.26 | 0.40 | 0.25 |
| Current Ratio | 0.64 | 0.64 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $844.4M | $844.4M | $706.6M | $708.4M | $397.3M |
| Returns | |||||
| ROE | 7.6% | 7.6% | 9.1% | 4.4% | 2.8% |
| Valuation | |||||
| P/E | 5.89 | 5.89 | 8.78 | 23.55 | 26.81 |
| EV/EBITDA | 2.39 | 2.39 | 3.70 | 5.77 | 6.64 |
| P/B | 0.51 | 0.51 | 0.80 | 1.02 | 0.75 |
| Growth & Yield | |||||
| Revenue Growth | -6.9% | -6.9% | -2.5% | 27.9% | — |
| EPS Growth | — | — | 125.0% | -4.8% | — |
| Dividend Yield | 5.6% | 5.6% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-26.8%
Start / end P/E
n/dx → n/dx
EPS bridge
0.45 → n/d
Residual
-32.4%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.